Treating Lewy Body Dementia by Targeting Patients Without Tau Protein

This patent describes a method to treat a specific type of Dementia with Lewy Bodies in patients who don't have a lot of another brain protein called tau, using a special kind of drug.

What it covers

The patent provides methods and compositions for treating subjects diagnosed with Dementia with Lewy Bodies (DLB). It specifically focuses on a population of patients who have DLB but do not show 'substantial tau pathology' in their brains, meaning they don't have a significant buildup of tau protein. These specific patients are shown to respond particularly well to treatment with a 'selective p38α mitogen activated protein kinase (MAPK) inhibitor'. For example, a patient diagnosed with DLB who tests negative for high levels of tau protein could be given a drug that specifically blocks the p38α MAPK pathway.

What it doesn't cover

• —Does not cover treating Dementia with Lewy Bodies in patients who do have substantial tau pathology, as they are shown to be less responsive.
• —Does not cover treatments for other forms of dementia, such as Alzheimer's disease, unless they also present as DLB without substantial tau pathology.
• —Does not cover general p38α MAPK inhibitors; it specifies a selective p38α MAPK inhibitor, implying a need for targeted action.
• —Does not cover treatments for DLB that are not based on inhibiting p38α MAPK.

The clever bit

The novelty lies in identifying a specific subgroup of Dementia with Lewy Bodies patients—those without substantial tau pathology—who are uniquely responsive to p38α MAPK inhibitors. This suggests a targeted treatment approach rather than a one-size-fits-all therapy, improving the chances of treatment success.

Why it matters

This patent highlights a personalized medicine approach for Dementia with Lewy Bodies, suggesting that treatment efficacy can be improved by identifying specific patient subgroups. By focusing on patients without substantial tau pathology, it aims to provide a more effective therapeutic strategy for a challenging neurodegenerative condition. This could lead to better outcomes for a subset of DLB patients who currently have limited treatment options.

Real-world examples

• 1.Targeted therapies for neurodegenerative diseases
• 2.Precision medicine approaches in neurology
• 3.Drug development for Dementia with Lewy Bodies